Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

Digital pharma Celgene GNS HealthcareCelgene is set to apply machine learning to market access, commercialisation and drug discovery through a partnership with GNS Healthcare.

GNS applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients.

The service and license arrangement with Celgene covers its REFS (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform.

The deal, which involves Celgene's second equity investment in the firm, will also see several GNS causal modeling experts brought in-house at the biopharma company's sites to operate the platform.

Iya Khalil, chief commercial officer and co-founder of GNS, said: “Companies that embrace data-driven frameworks and culture such as Celgene are gaining a competitive advantage to rapidly generate insights that are simply not possible with any other analytics methodology.”

In addition to Celgene, GNS has previously worked with the likes of J&J, Novartis, Covance and the US National Institutes of Health.

5th January 2017

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....